CLINICAL TRIALS and Important Links

[Maia]

NCT02834052
"Pembrolizumab + Poly-ICLC in MRP Colon Cancer"

https://clinicaltrials.gov/ct2/show/NCT02834052

(That is: Pembrolizumab (Keytruda) + Poly-ICLC (Hiltonol; experimental viral mimic and broad activator of innate immunity) in MRP ( = MSS) Colon Cancer"

Not yet recruiting. Only at Georgia Cancer Center, at Augusta University

"Current clinical trials are showing that patients whose tumors are mismatch repair deficient (MSI) are more likely to respond to immune-boosting anti-PD-1 drugs—such as pembrolizumab—than those with tumors proficient in mismatch repair (MRP or MSS). The idea is that the greater the number of DNA glitches in a tumor cell, the more abnormal proteins it will produce—and the more abnormal proteins that are generated, the greater the odds that the body's immune cells will regard the tumor cells as "foreign" and target them for destruction. Thus far, PD-1 inhibitors have shown great promise for mismatch repair deficient cancer patients, but not for mismatch repair proficient (MRP) cancer patients.

In this clinical trial, the investigators hypothesize that treating MRP colon cancer patients with immunostimulating agent poly-ICLC will generate an inflammatory response, increasing epitope recognition and development of tumor reactive T-cells at the tumor site. However, interferon alpha and gamma produced by the poly-ICLC will increase PD-L1 expression and limit new T-cell development. Thus, PD1 blockade will increase the effectiveness of treatment with pembrolizumab."

Description of Poly-ICLC: http://adisinsight.springer.com/drugs/800001705
Activating the Natural Host Defense
Hiltonol (Poly-ICLC) : http://www.oncovir.com/id2.html

[Maia]

NCT02860546
A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC

An interesting trial, aimed exclusively to microsatellite stable CRC (the %85 of CRC). It combines TAS-102 (Lonsurf, oral, approved for mCRC) with nivolumab (Opdivo, anti PD-1 immunotherapy, approved for many other cancers; it would be an off-label use). (Not medical advice but the point is that the trial combination might be reproducible under the care of some oncologist who judges this worhty.)



*Only for MSS
*TAS-102 (Lonsurf) + nivolumab (Opdivo)
*Phase II. Non randomised.
*Does allow prior treatment with Lonsurf or any other checkpoint inhibitor
*Colorado, Florida, Tennessee

https://clinicaltrials.gov/ct2/show/NCT02860546

[Maia]

NCT02991196
Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer

*Only mismatch repair (MMR)-proficient (=MSS) advanced colorectal cancer.
*Antibody DS-8273a + Nivolumab (=agonistic TRAIL-R antibody DS-8273a + anti-PD-1)
*DS-8273a: decrease in myeloid-derived suppressive cells (MDSC)
*Columbia and Texas; some locations still not recruiting
*a phase I trial in Solid tumours and Lymphoma (Late stage disease) completed 2015 (NCT02076451)

https://clinicaltrials.gov/ct2/show/NCT02991196

December 2, 2016: Selective targeting of myeloid-derived suppressor cells in cancer patients using DS-8273a, an agonistic TRAIL-R2 antibody J. Bendell et al. https://drive.google.com/open?id=0Bwc5k ... 20xOHl1U2M

[CRguy]

Just a quick note to inform folks of yet another major posting by our resident "rock star" scientist !

DK37 has started his own topic A DK37 CURATED MSS-CRC CLINICAL TRIAL FINDER!
which links directly to the new web app http://colorectalmsstrials.org/
also accessible through its introduction page at http://bit.ly/2jaj7tc

with a little help from a couple of good friends, Maia and Jana !

Thank you once again for a job well done.



UPDATED INFO : as of May 16,2017
in this topic NEW DK37 AND MAIA MSS-CRC CLINICAL TRIAL FINDER!

Links:
Trial finder: http://trialfinder.fightcrc.org/
My personal blog on the trial finder: https://adventuresinlivingterminallyopt ... al-finder/
Fight CRC's Press Release: https://fightcolorectalcancer.org/blog/ ... -released/

[CRguy]

I just updated the Calling ALL Colorectal CANUCKS ! topic with some recently discussed links from a Canadian senior's magazine
Some New Links for info about Clinical Trails in Canada and around the globe !

[mariobryant]

The purpose of this study https://www.mskcc.org/cancer-care/clini ... als/15-048 is to assess the safety of combining two drugs, varlilumab and nivolumab, in patients with advanced solid tumors that have continued to grow despite treatment. Varlilumab is an investigational drug that binds to a protein on immune cells called CD27, which makes the immune system stronger. Nivolumab is a form of immunotherapy. It works by attaching to and blocking a molecule called PD-1, which shuts down the immune response. It is hoped that by binding to these proteins, this drug combination can activate the immune system and enhance the body’s ability to detect and destroy cancer cells.

[Steph20021]

My friend will likely be trying Tremelimumab with Durvalumab in Toronto under NCT02870920 but he has been told he has to do a targeted therapy first. Folfiri and Folfox have already failed him. I'll post any updates here that he has if and when he finally gets accepted into the trial -hopefully soon. I'm going to read up on Maia's links on the combo now.

NCT02888743
Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer
https://clinicaltrials.gov/show/NCT02888743

Not yet recruiting. At Dana-Farber - Harvard Cancer Center. Boston, Massachusetts.

All 3 arms receive the 2 immuno drugs: A: two drugs without radiation; B: two drugs with radiation at a low dose; C: B: two drugs with radiation at a higher dose.
Lesion to be radiated has to be in liver.
Only for MSS

(Patients on the CRC arm need to have: "Microbiology Susceptibility Subcategory (MSS) tumor as documented by either:
Immunohistochemistry (IHC) testing that does not suggest loss of MLH-1, MSH-2, PMS2 or MSH6
Polymerase chain reaction (PCR) testing that does not suggest microsatellite instability (MSI))

durvalumab (MEDI4736): anti PD-L1, similar to atezolizumab.
tremelimumab: anti-CTLA-4, similar to ipilimumab.
More about the combination here: (May 2014) viewtopic.php?f=1&t=46727 and (Nov 2015) viewtopic.php?f=1&t=52938

[CRguy]

Looking for participants with advanced lung or colorectal cancer to undergo a combined treatment with different targeted therapies
More info and site information is available at this link : colorectal cancer Clinical Trial

In a nutshell
This phase 1/2 trial aims to study the safety and effectiveness of the treatment with different targeted therapy in patients with advanced lung or colorectal cancer. The main outcome to be measured is the response rate of the tumor to the treatment and the negative side effects. This trial is recruiting in California, Illinois and Texas, United States.

How will it work
Patients will receive increasing doses, by injection, of azacitidine over days 1 and 7, pembrolizumab over 30 minutes every 3 weeks on day 1 and epacadostat tablets twice daily. Treatment will repeat until disease progression or unacceptable side effects. Participants will be followed for up to 18 months.

[Capri]

As a caregiver and new to this site, I want to thank all the posters for this valuable information, how-tos and links. Very important and so helpful!

[CRguy]

A couple of new links added for today :

BCCA Medical Cannabis clinical trial

New Colon Club Blog Post - Clinical Trials

[CRguy]

Looking for patients with advanced colorectal cancer to a test two different treatment combinations
https://medivizor.com/view_article/2326 ... dium=email

This phase 3 trial is examining the effectiveness of arfolitixorin versus leucovorin (folinic acid) when added to a combined treatment with 5-fluorouracil, oxaliplatin, and bevacizumab (FOB) to treat advanced colorectal cancer. The main outcome to be measured is the cancer response to the treatment.

[tumblrnthings]

Which immunotherapy clinical trials are available for different cancers?

[O Stoma Mia]

Which immunotherapy clinical trials are available for different cancers?

For CRC tumors that are microsatellite stable (MSS), the following specialized trial finder can be used:

http://trialfinder.fightcrc.org/




For all other types of cancers you can use the general search procedure found on the clinicaltrials.gov website:
https://clinicaltrials.gov/ct2/search/index

For example,
https://clinicaltrials.gov/ct2/results?cond=colon+cancer&term=immunotherapeutic+agent&cntry=&state=&city=&dist=

[Green Tea]

ANCORA Clinical Trial Finder

Our Vision and Values

We use technology and a patient-first approach to democratize clinical trial access, so that every patient has the best chances of recovery and leading a healthy life.

We provide unbiased clinical trial information by collecting information from public registries so that patients, their healthcare professionals, and their loved ones can evaluate all potential treatment options. We believe it is important that every patient has a full overview of their options, separate from financial interests in the industry.

How do I find a trial?

You can use Ancora to search for clinical trials that might be suitable for you or your loved one. First fill in the four fields about the patient in question on the home page: the medical condition and age of the patient, and their location and willingness to travel. Then click “Find My Trials”. You can then view a list of search results.

https://www.ancora.ai/cancertrialsearch

[zephyr]

ANCORA Clinical Trial Finder

You can use Ancora to search for clinical trials that might be suitable for you or your loved one. First fill in the four fields about the patient in question on the home page: the medical condition and age of the patient, and their location and willingness to travel. Then click “Find My Trials”. You can then view a list of search results.

https://www.ancora.ai/cancertrialsearch

Thanks for posting. This trial finder seems easier to navigate than others I've used.